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Lee J, Cummings BP, Martin E, Sharp JW, Graham JL,
Stanhope KL, Havel PJ, Raybould HE. Glucose sensing by gut
endocrine cells and activation of the vagal afferent pathway is im-
paired in a rodent model of type 2 diabetes mellitus. Am J Physiol
Regul Integr Comp Physiol 302: R657–R666, 2012. First published
December 7, 2011; doi:10.1152/ajpregu.00345.2011.—Glucose in the
gut lumen activates gut endocrine cells to release 5-HT, glucagon-like
peptide 1/2 (GLP-1/2), and glucose-dependent insulinotropic poly-
peptide (GIP), which act to change gastrointestinal function and
regulate postprandial plasma glucose. There is evidence that both
release and action of incretin hormones is reduced in type 2 diabetes
(T2D). We measured cellular activation of enteroendocrine and en-
terochromaffin cells, enteric neurons, and vagal afferent neurons in
response to intestinal glucose in a model of type 2 diabetes mellitus,
the UCD-T2DM rat. Prediabetic (PD), recent-diabetic (RD, 2 wk
postonset), and 3-mo diabetic (3MD) fasted UCD-T2DM rats were
given an orogastric gavage of vehicle (water, 0.5 ml /100 g body wt)
or glucose (330 mol/100 g body wt); after 6 min tissue was removed
and cellular activation was determined by immunohistochemistry for
phosphorylated calcium calmodulin-dependent kinase II (pCaMKII).
In PD rats, pCaMKII immunoreactivity was increased in duodenal
5-HT (P  0.001), K (P  0.01) and L (P  0.01) cells in response
to glucose; glucose-induced activation of all three cell types was
significantly reduced in RD and 3MD compared with PD rats. Immu-
noreactivity for GLP-1, but not GIP, was significantly reduced in RD
and 3MD compared with PD rats (P  0.01). Administration of
glucose significantly increased pCaMKII in enteric and vagal afferent
neurons in PD rats; glucose-induced pCaMKII immunoreactivity was
attenuated in enteric and vagal afferent neurons (P 0.01, P 0.001,
respectively) in RD and 3MD. These data suggest that glucose sensing
in enteroendocrine and enterochromaffin cells and activation of neural
pathways is markedly impaired in UCD-T2DM rats.
5-hydroxytryptamine; intestinal glucose; incretin
TYPE 2 DIABETES MELLITUS (T2DM) is associated with the devel-
opment of obesity and characterized by the impaired ability of
gut hormones to regulate plasma levels of glucose and altera-
tions in energy balance (10). A substantial portion of insulin
secretion in response to oral ingestion of glucose is mediated
via release of the incretin hormones glucose-dependent insuli-
notropic polypeptide (GIP) and glucagon-like peptide (GLP-1).
GIP and GLP-1 are released from K and L gut enteroendocrine
cells (EECs), respectively, in response to luminal glucose and
augment glucose-stimulated insulin secretion (20, 25). How-
ever, patients with T2D demonstrate an impaired incretin
response resulting in insufficient insulin secretion from the
pancreatic -cell in response to ingestion of glucose (27).
Whether this impairment of the incretin response in T2D is due
to altered release of incretins and impaired incretin action at the
pancreatic -cell has been an area of controversy. There is
evidence that plasma levels of GIP following oral glucose are
not different between healthy controls and patients with T2D,
but that there is a decrease in the release of GLP-1 (39).
However, other evidence suggests that decrease -cell re-
sponse to incretin hormones in T2D patients (9). Thus altered
function in gut endocrine cells may play a role in the patho-
genesis of T2DM; however, in vivo studies looking at direct
activation of these cell populations have been limited, in part,
due to the difficulty in studying this cell population in vivo.
Glucose-sensing mechanisms by K and L cells have been
extensively studied using in vivo models and EEC lines and
have identified a number of possible mechanisms. Recent
studies using cultures of highly purified K or L cell culture
have suggested that KATP channels and possibly the sodium-
glucose cotransporter SGLT-1 play a predominant role in
glucose sensing (14, 26, 35). There is also evidence that taste
transduction elements including the G protein-coupled sweet
taste receptors T1R1/3 may also sense glucose in the gut (18).
Luminal glucose also induces release of 5-hydroxytrypta-
mine (5-HT) from enterochromaffin (EC) cells in the gut wall.
Receptors for 5-HT are expressed by many different cell types
in the gut wall, and 5-HT activates intrinsic reflexes to regulate
motor and secretory function. 5-HT also activates extrinsic,
vagal afferent terminals located in the gut wall via 5-HT3
receptors (5-HT3Rs) to activate a vago-vagal reflex to inhibit
gastric emptying and stimulate pancreatic exocrine secretion
(19, 24). Interestingly, there is evidence that vagal efferent
outflow can also influence the secretion of incretin hormones to
maintain glucose homeostasis (4, 29, 37). Loss of vagal func-
tion also results in a reduced incretin effect, demonstrating
the importance of peripheral neuroendocrine loop to regulate
plasma glucose in the postprandial period (29).
The UCD-T2DM rat is a relatively new animal model of
human T2DM demonstrating polygenic adult-onset obesity
and insulin resistance accompanied by -cell dysfunction. It
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more closely models the pathophysiology of adult-onset T2DM
in humans than other rodent models of the disease (7). We
hypothesized that in T2DM, glucose sensing in the gut wall
would be impaired. During the onset and progression of
T2DM, cellular activation of ECs and EECs in response to
luminal glucose would be reduced along with diminished
activation of the gut-brain axis. We have recently developed a
method for measuring activation of gut EECs and ECs in situ,
avoiding the use of either cell lines or isolated cell preparation
(40). This technique uses detection of phosphorylated calcium
calmodulin-dependent kinase II (pCaMKII) by immunohisto-
chemistry as a marker of cellular activation. Moreover, the
ability to conduct experiments in unanesthetized rats allows us
to assess the activation of intrinsic and extrinsic neurons along
the gut-brain axis.
MATERIALS AND METHODS
Animals. The UCD-T2DM model was developed by breeding
Sprague-Dawley rats with adult-onset obesity and insulin resistance
with Zucker diabetic fatty-lean rats. UCD-T2DM rats have a pancre-
atic -cell function defect in combination with polygenic adult onset
obesity that results in development of T2DM, which closely resembles
the pathophysiology of T2DM in humans (7). These rats have no
defect in leptin receptor signaling. Male UCD-T2DM rats classified as
prediabetic (PD), recently diabetic (RD, 2 wk postonset), or long-term
diabetic (3MD, 3-mo postonset) were given ad libitum access to
standard chow and water and housed in a controlled environment with
a 10-h:14-h light/dark cycle. Diabetes onset is defined as a nonfasted
blood glucose concentration greater than 200 mg/dl on two consecu-
tive weeks. Animals were maintained and handled in accordance with
protocols approved by the institutional Animal Care and Use Com-
mittee (University of California, Davis).
Experiments and tissue collection. Body weight was recorded
throughout the experimental period. Rats were fasted overnight in
wire-bottom cages with free access to water. Rats were given an oral
gavage of vehicle (0.5 ml water/100 g body wt) or glucose (0.5 ml of
330 mol/100 g body wt); 6 min following gavage, rats were deeply
anesthetized with pentobarbital sodium (100 mg/kg ip) and transcar-
dially perfused with 0.9% NaCl with 0.1% heparin at 4°C followed by
1 ml/g body wt of 4% paraformaldehyde dissolved in PBS (PFA-PBS)
Fig. 1. A: photomicrographs to show immunoreactivity for 5-HT (a; left, red) and phosphorylated CaMKII (b; right, green) in sections of duodenum following
oral gavage of water (vehicle) (i) in prediabetic (PD) rats or glucose in PD (ii), recently diabetic (RD; iii), or 3 mo diabetic (3MD; iv) rats. In PD rats, orogastric
gavage of glucose induced a significant increase in pCaMKII immunoreactivity compared with administration of water as indicated by numerous pCaMKII-
labeled cells (ib vs. iib). The level of immunoreactive pCaMKII in enterochromaffine cells (ECs) following administration of glucose in RD and 3MD rats is
much reduced compared with PD rats (iib vs. iiib and ivb). B: quantitative analysis of pCaMKII immunoreactivity in EC cells; pCaMKII in response to glucose
gavage was significantly reduced in RD and 3MD rats compared with PD rats. C: quantitative analysis of 5-HT immunoreactivity in ECs from vehicle-treated
PD, RD, and 3MD rats; there was a trend for a decrease in 5-HT immunoreactivity in the duodenum of 3MD rats compared with PD, but this did not reach
statistical significance. Data are expressed as means  SE, n  3–5 rats per group, 48–67 cells/analyzed per treatment group. Significant differences between
PD and RD or 3MD denoted by different letters; P  0.001.
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at 4°C. Small intestine and nodose ganglia were rapidly removed and
postfixed for 2 h in 4% PFA-PBS before transfer and storage at 4°C
in 25% sucrose dissolved in PBS until processing.
Immunohistochemistry. A portion of the duodenum, 7 mm  7
mm, was taken about 2 cm distal of the pyloric-duodenal junction.
Frozen horizontal sections of 8 m thickness from duodenal crypts
were cut by cryostat and mounted onto coated slides (Fisher Super-
frost Plus, Fisher Scientific, Pittsburgh, PA). Six to ten tissue sections
for each antibody combination were cut from tissue from each rat.
Slides were desiccated on a warming table and washed in 0.1 M
phosphate buffer (PBS, 3 10 min each), then blocked with 20% goat
serum dissolved in PBS for 30 min at 37°C incubation.
The following antibodies were employed in this study: anti-pCaM-
KII (1:200 dilution, pT286 rabbit IgG polyclonal antibody, V111A,
Promega, Madison, WI); anti-serotonin (5-HT) (1:1,000 dilution,
mouse monoclonal antibody, MO758, Dako, Carpinteria, CA); anti-
GIP (1:100 dilution, rabbit polyclonal antibody, Chemicon, Temecula,
CA); and anti-GLP-1 (diluted 1:100, rabbit polyclonal antibody,
ab22625, Abcam, Cambridge, MA). All primary antibodies were
incubated at 37°C for 2.5 h. After 3 10-min PBS washes, tissues were
incubated with secondary antibodies (goat anti-rabbit IgG AlexaFluor
488, A11034; goat anti-mouse AlexaFluor 546, A11030; or goat anti-
rabbit IgG AlexaFluor 546, A11035, Molecular Probes, Eugene, OR).
Secondary antibodies were diluted 1:500 in 2% GS-PBS and incubated at
37°C for 30 min.
Tissue sections were double labeled with two different primary
antibodies. If primary antibodies were from two different species,
antibodies were coincubated. If the antibodies were both rabbit poly-
clonal antibodies, the incubations were sequential. The anti-5-HT and
pCaMKII antibodies were made in different species, incubated to-
gether, and identified with anti-mouse 546 and anti-rabbit 488 sec-
ondary antibodies, respectively. The anti-pCaMKII and anti-GIP/anti-
GLP-1 are all rabbit polyclonal antibodies, thus requiring a sequential
immunohistochemistry procedure. One complete immunohistochem-
istry protocol was completed for the first primary antibody (anti-
pCaMKII), which was followed immediately by a complete protocol
for the second primary antibody (anti-GIP or anti-GLP-1). The first
primary antibody (anti-pCaMKII) was incubated at 37°C for 2.5 h
followed by 3 10-min PBS washes. The first secondary antibody
(anti-rabbit 488) was added and incubated for 30 min at 37°C. Slides
were then washed with 0.1 M PBS 1 10 min at room temperature
followed by an overnight wash at 4°C in PBS. The second blocking
step consisted of two steps; tissue was blocked with 20% normal
rabbit serum (S-5000,Vector Labs, Burlingame, CA) in PBS for 30
Fig. 2. A: photomicrographs to show immunoreactivity for glucose-dependent insulinotropic polypeptide (GIP) (a; left, green) and pCaMKII (b; right, red) in
sections of duodenum following oral gavage of vehicle (i) in PD rats or glucose in PD (ii), RD (iii), or 3MD (iv) rats. In PD rats, orogastric gavage of glucose
induced a significant increase in pCaMKII immunoreactivity compared with administration of water as indicated by pCaMKII-labeled cells (ib vs. iib). After
administration of glucose in RD and 3MD rats, levels of pCaMKII immunoreactivity in GIP cells were much reduced compared with PD rats (iib vs. iiib and
ivb). B: quantitative analysis of pCaMKII-IR in GIP cells; pCaMKII-IR in response to glucose gavage was significantly reduced in RD and 3MD rats compared
with PD rats. C: quantitative analysis of GIP immunoreactivity showed no significant difference in GIP expression between PD, RD, and 3MD rats. Data are
expressed as means  SE, n  3–4 rats per group; 31–44 cells analyzed/treatment group. Significant differences between PD and RD or 3MD denoted by
different letters; P  0.01.
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min at 37°C followed with 3 PBS washes. Second, slides were
incubated with monovalent unconjugated goat anti-rabbit F(ab) (111–
007-003, Jackson ImmunoResearch, West Grove, PA) diluted 20
g/ml for 30 min at 37°C. These steps prevent nonspecific binding of
the second primary and secondary antibodies. After 3 PBS washes,
the second primary antibody, either anti-GIP or anti-GLP-1, was
incubated for 2.5 h at 37°C. After 3 PBS washes, the second
secondary antibody goat anti-rabbit 546 was incubated for 30 min at
37°C. Slides were then washed with 0.1 M PBS 1 10 min at room
temperature followed by an overnight wash at 4°C in PBS.
Slides were coverslipped using GelMount (Biomeda, Foster City,
CA) and dried in the dark at room temperature. Slides were stored at
20°C until imaging. Fixed neural tissues of nodose ganglia had
identical slide preparation as gut tissue; the primary antibody was
pCaMKII and goat anti-rabbit IgG conjugated AlexaFluor 488 sec-
ondary antibody.
Specificity of the anti-pCaMKII antibody was confirmed with a
CaMKII (phosphor Thr286) blocking peptide from GenScript (RP
19957), which blocks labeling by the Promega anti-pCaMKII anti-
body under the experimental conditions outlined above.
Image acquisition and analysis. Images were made with a confocal
microscope (Bio-Rad, Radiance System 2100, Hercules, CA; Olympus
Confocal Microscope, Center Valley, PA) using exactly the same acqui-
sition parameters for each image for a specific tissue or cell type. Images
were changed to a gray-level image in Photoshop (Adobe Systems, San
Jose, CA) and then analyzed in Scion Image (Scion, Frederick, MD).
Pixels above a threshold brightness were considered to be immunoposi-
tive and were then summed by the computer software. The threshold
level was determined by the investigator and applied uniformly. The
threshold value was typically chosen at a brightness level three times that
of background for a specific cell type or tissue.
K cells (GIP), L cells (GLP-1), and 5-HT cells were analyzed as
individual cells. Scion software was used to draw around the plasma
membrane of the cell; this defined a region of interest to be analyzed.
This threshold value was kept constant for all analyzed cells. Pixels at
or above the threshold were counted as immunopositive. The number
of immunopositive pixels was summed by the software for the entire
cell. The whole area of the cell, in pixels, was determined by adjusting
the threshold so that the entire area of the cell could be determined.
Next the region of the cell’s nucleus was drawn around, and the
number of labeling pixels in the nucleus and the number of pixels in
the entire nucleus was determined. With the use of these values, the
percent labeled pixels in the whole cell and in the nucleus can be
calculated. The number of labeled pixels in the nucleus was subtracted
Fig. 3. A: photomicrographs to show immunoreactivity for glucagon-like peptide-1 (GLP-1) (a; left, green) and pCaMKII (b; right, red) in sections of duodenum
following oral gavage ofvehicle (water) (i) in PD rats or glucose in PD (ii), RD(iii) or 3MD (iv) rats. In PD rats, orogastric gavage of glucose induced a significant
increase in pCaMKII immunoreactivity compared with administration of water as indicated by pCaMKII-labeled cells (ib vs. iib). After administration of glucose
in RD and 3MD rats, levels of immunoreactive pCaMKII in GLP-1 cells are much reduced compared with PD rats (iib vs. iiib and ivb). B: quantitative analysis
of pCaMKII immunoreactivity in GLP-1 cells; pCaMKII expression in response to glucose gavage was significantly reduced in RD and 3MD rats compared with
PD rats. C: quantitative analysis of GLP-1 immunoreactivity shows a significant decrease in levels in RD and 3MD rats compared with PD controls. Data are
expressed as means  SE, n  3–4 rats per group; 32–44 cells analyzed per group. Significant differences between PD and RD or 3MD denoted by different
letters a and b; P  0.01.
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from the whole cell to give the number of labeled pixels in the
cytoplasm. For proteins such as pCaMKII, which is not found in the
nucleus, any labeling in the nucleus was considered as background
labeling. If the nucleus has 0.2% pCaMKII labeling and the cytoplasm
has 5% labeling, the labeling in the cytoplasm was normalized by
subtracting the percent labeling in the nucleus from the cytoplasmic
labeling. In this example it would be 4.8%.
For the submucosal and myenteric plexus, the number of pixels
for the entire plexus was determined by using the software to draw
around the margin of the plexus, raising the threshold to saturation and
measuring the total number of pixels in the plexus. Dividing the area of
labeled pixels by the total area of the plexus 100 then results in an index
of pCaMKII expression in terms of percent labeled pixels for the plexus.
Quantification of immunoreactivity is presented as either percent
labeled pixels or percent labeled cells over total area normalized by a
set baseline threshold value as previously described (40). A cell was
considered to be a labeled, reactive, cell if 20% or more of its
cytoplasmic area was immunopositive for pCaMKII.
Statistical analysis. A total of 27 rats were used in this study; n 
9 PD, RD, and 3MD, respectively. Data were analyzed using Scion
Image software (NIH Image for Windows, Beta 4.0.2 Scion, 2000) for
individual neuron images and data analyzed by Prism GraphPad
(v.5.02) and are represented as mean values  SE and analyzed by
one-way ANOVA to determine statistical significance (P  0.05),
followed by Bonferroni’s post-hoc test.
RESULTS
Metadata. The mean age of the rats at time of experiment
were 128  5, 122  4, and 222  20 days old, with body
Fig. 4. A: photomicrographs to show immunoreactivity for pCaMKII in the submucosal plexus of the duodenum from PD, RD, and 3MD rats following orogastric
gavage with vehicle (i–iii, top) or glucose (iv–vi, bottom). B and C: quantification of immunoreactivity for pCaMKII in submucosal neurons in response to
orogastric gavage or vehicle administered to PD, RD, and 3MD rats. B: data expressed as percent labeled pixels. C: data expressed as percent labeled neurons.
Data are expressed as means  SE, n  4–5 rats per group; 39–50 plexuses imaged and 197–361 neurons/treatment group analyzed. Significant differences
between PD and RD or 3MD denoted by different letters; P  0.01. Scale bar  50 m.
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weights of 594 16, 582 18, and 562 18 g and nonfasting
glucose concentration of 145  6, 432  35, and 476  23
mg/dl for PD, RD, and 3MD, respectively. The RD rats had
been diabetic for 10  1 days and the 3MD for 93  1 days.
pCaMKII immunoreactivity in duodenal 5-HT, GIP, and
GLP-1 immunoreactive cells in response to glucose in T2DM
rats. Gavage of glucose produced a significant increase in
pCaMKII expression in 5-HT-immunoreactive cells in PD rats
compared with vehicle treatment. This increase in immunore-
active pCaMKII to glucose was significantly reduced in RD
and 3MD rats to near nadir levels (Fig. 1, A and B; P 0.001).
In addition, there was a reduction in 5-HT immunoreactivity in
3MD but not RD compared with PD rats (Fig. 1C), although
this did not reach statistical significance. Immunoreactivity for
pCaMKII in duodenal K cells was significantly increased in
response to intestinal glucose in PD rats compared with vehicle
treatment, but there was no increase in response to glucose in
RD and 3MD rats (Fig. 2, A and B, P  0.01). Similarly,
glucose-induced expression of pCaMKII in duodenal L cells
was increased in PD rats but not in RD and 3MD rats (Fig. 3,
A and B; P  0.01). There was a significant reduction in
immunoreactivity for GLP-1 in L cells of both RD and 3MD
rats compared with PD rats (32% and 33% of PD levels,
respectively) (Fig. 3, A and C; P  0.01); however, there was
no change in GIP immunoreactivity with the three diabetic
groups (Fig. 2C).
Fig. 5. A: photomicrographs to show immunoreactivity for pCaMKII in the myenteric plexus of the duodenum from PD, RD, and 3MD rats following orogastric
gavage with vehicle (ddH2O) (top) or glucose (bottom). B: quantification of photomicrographs for immunoreactivity for pCaMKII in myenteric neurons in
response to orogastric gavage of glucose or vehicle administered to PD, RD, and 3MD rats. B: data expressed as percent labeled pixels. C: data expressed as
percent labeled neurons. Data are expressed as means  SE, n  3–4 rats per group; 30–40 plexuses imaged and 467–516 neurons/treatment group analyzed.
Significant differences between PD and RD or 3MD denoted by different letters; P  0.01. Scale bar  50 m.
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pCaMKII immunoreactivity in enteric and vagal afferent
neurons in response to glucose in T2DM rats. There was
minimal neuronal activation in the submucosal or myenteric plexus
following orogastric gavage with vehicle (Figs. 4A and 5A); glucose
treatment induced a significant increase in pCaMKII expres-
sion in both the submucosal and myenteric plexus from PD rats
(Figs. 4 and 5). Glucose-induced pCaMKII immunoreactivity
was significantly decreased in both the submucosal and myen-
teric plexus in RD and 3MD compared with PD rats (Figs. 4
and 5; P  0.01).
Similarly, activation of vagal afferent neurons in response to
intragastric gavage with glucose was significantly attenuated
with the onset and progression of diabetes. pCaMKII expres-
sion in nodose neurons was significantly increased in PD rats
treated with glucose compared with vehicle treatment; this was
significantly reduced in RD and 3MD rats to a level that was
not significantly different from PD rats treated with vehicle
(Fig. 6, A and B; P  0.001).
DISCUSSION
In the present study, we investigated whether glucose sens-
ing in gut EECs and ECs and in intrinsic and vagal afferent
neurons is impaired in a rodent model of T2DM. The data
show that glucose-induced activation of 5-HT, GIP, GLP-1
containing cells, as well as neurons of the ENS and the vagal
pathway are all markedly impaired in UCD-T2DM rats. This
suggests that T2DM is associated with impaired glucose sens-
Fig. 6. A: photomicrographs to show immunoreactivity for pCaMKII in nodose ganglia from PD, RD, and 3MD rats following orogastric gavage with vehicle
or glucose. B: quantification of photomicrographs for immunoreactivity for pCaMKII in nodose neurons in response to orogastric gavage of glucose. Data are
expressed as means  SE, n  3–6 rats per group; 477–1656 cells imaged/treatment. Significant differences between PD and RD or 3MD denoted by different
letters P  0.001. Scale bar  50 m.
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ing in the gut wall and transmission of this information via the
vagus nerve to the central nervous system. The inability of gut
ECs and EECs to respond to glucose and mount an adequate
incretin response or reflex changes regulate motor and secre-
tory function likely impairs the postprandial response to a meal
and may lead to dysregulation of postprandial levels of plasma
glucose.
In this study, we used pCaMKII immunoreactivity as an
index of cellular activation following in vivo treatment of rats
with intragastric glucose (31). This technique has the clear
advantage of being able to study the response of EECs and ECs
in situ, where the cells remain part of an intact and polarized
epithelium. Moreover, this technique allows for the study of
activated neuronal pathways downstream to the activation of
gut epithelial cells. Thus the possible consequences of defec-
tive glucose sensing in the gut EECs and ECs on activation of
intrinsic and extrinsic reflex pathways can be determined. One
possible confounding factor may be differences in gastric
emptying between prediabetic and diabetic rats; we have not
determined the rate of gastric emptying in this model. There is
conflicting data on the rate of gastric emptying of liquids from
patients with T2D, with studies showing no difference in
emptying rates of glucose in T2D patients and healthy controls
and another showing more rapid emptying of glucose in T2D
patients (2, 17). Similarly, OLETF rats demonstrate no deficit
in gastric emptying relative to control rats (8), whereas strep-
tozotocin-induced diabetic mice have accelerated gastric emp-
tying (38).
Serotonin is an amine mediator that is abundant in the gut
wall. We have previously shown that glucose induces the
release of 5-HT from ECs; 5-HT subsequently binds to
5-HT3Rs on vagal afferent nerve terminals in the gut mucosa to
activate vago-vagal reflexes important in regulation of gastric
emptying as well as mediating glucose-induced reductions in
food intake (11, 30, 42). Previous work has suggested that
5-HT cell content of the gut is reduced in rodent models of
obesity and diabetes compared with control animals (3, 32, 33),
but activation of these cells in vivo in the UCD-T2DM model
has not been previously investigated. We observed that acti-
vation of 5-HT cells is markedly reduced in RD and 3MD rats.
The mechanisms leading to this attenuated cellular activation
in response to glucose is not clear and was not investigated in
this study but may involve alterations in the sensing mecha-
nism itself, such as changes in expression of SGLTs, sweet-
taste receptors or other proteins, or may be due to more
nonselective changes in intracellular pathways involved in
secretion from the gut EECs. Reduced activation of EECs may
contribute to the overall reduced ability to sense luminal
glucose, leading to the hyperphagia observed in untreated
T2DM.
Impaired incretin action of GIP and GLP-1 has been impli-
cated as a large contributing factor in the development and
progression of T2DM (5). This is supported by observations
that nutrient-stimulated insulin secretion is blunted with re-
duced incretin function in T2DM (1, 16). However, the mech-
anisms by which GLP-1 and GIP activity are attenuated appear
to be different since diabetic subjects remain sensitive to
exogenously administered GLP-1 but become insensitive to
exogenous GIP (23). Our finding that glucose-induced activa-
tion of K cells as measured by pCaMKII is reduced in rats with
T2DM suggests that GIP cells may have an impaired ability to
respond to luminal glucose. This is consistent with observa-
tions that insulinotropic activity of GIP is reduced in T2DM
(21), suggesting that there may be a defect in K cell signaling
and secretion.
Our finding that GLP-1 hormone content and L cell activa-
tion is reduced in UCD-T2DM rats is in line with previous
reports showing reduced plasma GLP-1 activity in animal
models of T2DM and in diabetic humans (34, 39). GLP-1
secretion from the distal ileum is dependent, at least in part, on
a GIP-driven enteroendocrine reflex loop (28). Under diabetic
conditions, reduced GIP release from K cells may lead to a
decrease in stimulation of GLP-1 release from distal L cells.
We did not find any differences in ileal GLP-1 content (un-
Table 1. Number of rats, enteric plexuses, nodose ganglia, and epithelial cells used for image analysis
Prediabetic Recent Diabetic 3 Mo Diabetic
H2O Glucose H2O Glucose H2O Glucose
5HT
rats 4 4 3 5 3 4
cells 52 57 48 67 48 56
GIP
rats 4 4 3 3 3 3
cells 44 42 33 31 31 34
GLP-1
rats 4 4 3 3 3 3
cells 44 43 39 32 36 33
Submucosal Plexus
rats 4 4 4 5 4 4
plexuses 40 40 39 50 40 40
cells 197 215 201 361 202 274
Myenteric Plexuses
rats 3 4 3 4 3 4
plexuses 32 40 31 40 30 40
cells 617 496 401 653 620 467
Nodose Ganglia
rats 3 6 3 6 3 6
cells 1,202 1,548 1,656 1,118 477 813
GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1.
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published observations) between pre- and diabetic rats, sug-
gests that there may be differences in the population of L cells
in the proximal versus the distal gut. Overall, the impairment of
duodenal K and L cell activity could be major factors contrib-
uting to impaired regulation of postprandial plasma glucose in
the UCD-T2DM rat.
The enteric nervous system is essential for monitoring gut
function and glucose homeostasis and has been shown to be
compromised in diabetes (15, 36, 41). Here, neuronal activa-
tion in response to glucose was significantly reduced within
both the submucosal and myenteric plexuses of rats with
T2DM. Whether the impaired neuronal response is due to
decreased release of 5-HT, for example, is not clear. However,
we cannot rule out the possibility that reduced neuronal re-
sponse may be due to compromised neuronal function. Chem-
ically induced diabetes has been shown to be associated with
altered enteric neuron size, population, and neurodegenerative
changes in rodent models (6, 22); there was no evident change
in the enteric neurons observed in the present study, but this
was not systemically examined.
Vagal efferent neuronal dysfunction has been demonstrated
in rodents and patients with T2DM (12, 33), although little
attention has previously been paid to afferent neural response
to nutrient stimuli. This is the first study to demonstrate
impaired activation along the vagal afferent pathway in a
model of T2DM. pCaMKII immunoreactivity was significantly
elevated in nodose ganglia of prediabetic UCD-T2DM rats
following glucose gavage, a response previously shown to be
induced by glucose and not caused by an osmotic effect (40);
around 26% of nodose neurons were activated by glucose,
which is higher than in our previous study. It should be noted
that not only are these a different strain of rats but that all of the
“prediabetic” controls would eventually go on to develop T2D
and thus there maybe some alteration in signaling or neuronal
function even in the prediabetic group. This activation may be
due to release of 5-HT or GLP-1 from gut EECs and ECs, as
vagal afferents express receptors for both. In addition, there is
some evidence for direct sensing of glucose by vagal afferent
neurons (13). Reduced vagal afferent neuron activity in T2DM
may be due, in part, to decreased 5-HT and incretin hormone
release, leading to impaired vagal afferent response to glucose
in the UCD-T2DM rat.
Perspectives and Significance
We have demonstrated that diabetes progression in the
UCD-T2DM rat is associated with reductions in 5-HT, L, and
K cell signaling, and subsequent decreases in activity of the
enteric nervous system and vagus nerve. This decreased ability
to detect luminal glucose and to mount appropriate humoral,
enteric, and vago-vagal reflex will likely contribute to altered
regulation of glucose homeostasis, insulin secretion, and food
intake in the postprandial period in T2DM.
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